Skip to main content

Market Overview

Novartis-Genmab's Kesimpta Gets EU Approval In Multiple Sclerosis

  • Novartis AG (NYSE: NVS) said that Kesimpta (ofatumumab) had won European Union approval as the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis.
  • The company is developing and marketing the product under a license agreement with Genmab A/S (NASDAQ: GMAB).
  • The approval follows a positive opinion issued for subcutaneous ofatumumab by the CHMP of the European Medicines Agency in January this year.
  • Ofatumumab is a fully human CD20 monoclonal antibody. It is self-administered by a once-monthly injection, delivered subcutaneously.
  • Price Action: NVS shares closed 0.7% lower at $87.35 on Monday; GMAB shares are up 0.3% higher at $32.2 in premarket trading on the last check Tuesday.

Related Articles (NVS + GMAB)

View Comments and Join the Discussion!

Posted-In: European Commission multiple sclerosisBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at